期刊文献+

PIK3CA基因在乳腺癌不同分子亚型中突变的研究 被引量:2

Study of PIK3CA Gene Mutation in Different Molecular Subtypes of Breast Cancer
下载PDF
导出
摘要 目的探讨PIK3CA基因在乳腺癌不同分子亚型中突变的关系。方法选取200例乳腺癌患者组织标本,其中luminal A、luminal B、HER-2过表达型、besal-like型各50例。提取DNA,用紫外光分光光度仪来测定浓度及含量,对exon9及exon20进行PCR扩增,扩增产物纯化后测序,另取20例乳腺腺病组织标本用作为对照,与基因库序列对比分析其突变的情况。结果 200例乳腺癌组织中发现突变64例,突变率32%,其中exon9突变26例(40%),exon20突变38例(60%),在乳腺癌分子亚型中:luminal A型中22例(44%),luminal B型中16例(32%),HER-2过表达型20例(40%),besal-like型6例(12%),突变分布有统计学意义(P<0.05)。在20例良性对照组中均没发现突变。PIK3CA基因突变与乳腺癌肿瘤患者肿瘤大小、年龄、淋巴结状态之间无明显相关性(P>0.05)。结论 PIK3CA基因在乳腺癌不同分子亚型中的突变有差异,与乳腺癌其他临床病理特征之间无明显相关性。 Objective To investigate correlation of PIK3 CA gene mutation in different molecular subtypes of breast cancer. Methods To select 200 cases of breast cancer tissue samples, The luminal subtype A, luminal subtype B, HER-2 over-expression subtype and besal-like subtype all the 50 cases. To extract DNA from samples of breast cancer, PCR amplification of exons 9 and 20 was done after determining the concentration and content by ultraviolet spectrophotometer, followed by sequence after the product was purified. Another 20 samples of adenosis of breast were chosen as controls. Results The frequency of PIK3CA mutations among 200 cases was 64 missense mutations (32%) , 26(40% ) in exon 9, 38(60% ) in exon 20 were found. In molecular subtype of breast cancer:22 (44%) in luminal subtype A , 16 (32%) in luminal subtype B,20(40% ) in HER-2 over-expression subtype, 6( 12% ) in besal-like subtype, mutations distribution had statistical significance (P 〈 0.05). No mutation was found in 20 cases of adenosis of breast. The mutation of PIK3CA gene had no significant correlation with age, tumor size and lymph node status(P 〉 0.05). Conclusion The mutations of PIK3CA gene with different molecular subtypes are different in breast cancer. However, there is no significant correlation between PIK3CA gene mutations and the pathological features of breast carcinoma.
出处 《河南科技大学学报(医学版)》 2014年第4期245-246,250,共3页 Journal of Henan University of Science & Technology:Medical Science
关键词 PIK3CA基因 突变 乳腺肿瘤 PIK3 CA gene mutation breast neoplasms
  • 相关文献

参考文献11

  • 1Agarwal G,Praddep PV,Aggarwal V,et al.Spectrum of breast cancer in Asian women[J].World.Surg,2007,31(5):1031-1040.
  • 2Levine DA,Bogomolniy F,Yee CJ,et al.Frequent mutation of the PIK3CA gene in ovarian and breast cancers[J].Clin Cancer Res,2005,11:2875-2878.
  • 3Massion PP,Taflan PM,Shayr Y,et al.Early involvement of the phosphatidylinositol 3-kinase/AKT pathway in lung cancer progression[J].Am J Respir Crit Care Med,2004,170:1088-1094.
  • 4Bachman K E,Argani P,Samuels Y,et al.The PIK3CA gene is mutated with high frequency in human breast cancers[J].Cancer Biol Ther,2004,3(8):772-775.
  • 5Isakoff S J,Engelman J A,Irie H Y,et al.Breast cancerassociated PIK3CA mutations are oncogenic in mammary epithelial cells[J].Cancer Res,2005,65(23):10992-11000.
  • 6Buttitta F,Felicioni L,Barassi F,et al.PIK3CA mutation and histological type in brest carcinoma:high frequency of mutations in lobular carcinoma[J].J Pathol,2006,208(3):350-355.
  • 7Park B H,Davidson N E.PI3 Kinase activation and response to trastuzumab therapy[J].Cancer Cell,2007,12(4):297-299.
  • 8Berns K,Horlings H M,Hennessy BT,et al.A unctional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer[J].Cancer Cell,2007,12(4):395-402.
  • 9Lee JW,Soung YH,Kim SY,et al.PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas[J].Oncogen,2005,24:1477-1480.
  • 10Campbell IG,Russell SE,Choong DY,et al.Mutation of the PIK3CA gene in ovarian and breast cancer[J].Cancer Res,2004,64:7678-7681.

同被引文献16

  • 1Lopez-Knowles E, O' toole SA, Mcneil CM, et al. PI3K pathway activation in breast cancer is associated with the basal like phenotype and cancer-specific mortality[J]. Int J Cancer,2010,126(5):1121-1131.
  • 2Kataoka Y, Mukohara T, Shimada H, et al. Association between gain of-function mutations in PIK3CA and re- sistance to HER2-targeted agents in HER2-amplified breast cancer cell lines[J]. Ann Oncol, 2010,21 (2) : 255- 262.
  • 3Cizkova M, Susini A, Vacher S, et al. PIK3CA mutation impact on survival in breast cancer patients and in ERa, PR and ERBB2-based subgroups[J]. Breast Cancer Res, 2012,14(1) :R28.
  • 4Von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66 ) : a randomised phase 2 trial[J]. Lancet Oncol, 2014,15(7):747-756.
  • 5Bozhanov SS, Angelova SG, Krasteva ME, et al. Ahera tions in p53,BRCA1,ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological charac teristics and overall survival of Bulgarian patients with breast cancer[J]. J Cancer Res Clin Oncol, 2010, 136 ( 11 ) :1657-1669.
  • 6Majewski I J, Nuciforo P, Mittempergher L, et al. PIK3CA mutations are associated with decreased benefit to neoad juvant human epidermal growth factor receptor 2 targeted therapies in breast cancer[J]. J Clin Oncoi,2015,33(12) : 1334-1339.
  • 7Henry NL, Schott AF, Hayes DF. Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-posi rive breast cancer: clinical validity but not utility[J]. J Clin Oncol,2014,32(29) :3207 3209.
  • 8李少英,王维,李建梅,王尊,温瑞英,陈静,缪小佟.PIK3CA基因突变与乳腺癌恶性程度和预后的关系[J].中华肿瘤杂志,2011,33(8):605-608. 被引量:4
  • 9胡沁,石园,侯英勇,何德明,李晓静,蒋冬先,黄洁,曾海英,宿杰阿克苏,谭云山.乳腺癌中PIK3CA基因突变与HER2表达及其基因扩增的关系[J].临床与实验病理学杂志,2013,29(5):477-481. 被引量:7
  • 10姚宇锋,龚建平,唐金海,秦建伟.多西他赛联合洛铂新辅助化疗方案治疗三阴性乳腺癌的临床观察[J].临床肿瘤学杂志,2013,18(8):723-725. 被引量:19

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部